The main aim of drug development is to get a compound that has a therapeutic effect into the form of a medicine we can dose to patients that is safe and effective. A drug must reach the site of action in a quantity sufficient to exert its pharmacological effects, and be eliminated in a reasonable timeframe. DMPK, an acronym that stands for drug metabolism and pharmacokinetics, considers how the drug is metabolized and processed by the body.

Pharmacokinetics (PK) is the study of the time course of the absorption, distribution, metabolism and excretion (ADME) of a drug, compound or new chemical entity (NCE) after its administration to the body. ADME test results can be used to predict how the drug will behave in the body and to assess its potential for adverse interactions with other drugs. Bioanalytical support plays a vital role during the lead optimization stages. The major goal of the bioanalysis is to assess the over-all ADME characteristics of the NCEs and biologics. Bioanalytical tools can play a significant role and impact the progress in drug discovery and development. Dramatic increases in investments in new modalities beyond traditional small and large molecule drugs, such as peptides, oligonucleotides, and ADC, necessitated further innovations in bioanalytical and experimental tools for the characterization of their ADME and PK properties.

Medicilon’s DMPK&BA department offers our clients a broad spectrum of high quality services in the areas of in vitro ADMET, in vivo PK & BA, and non-GLP Tox services for both small and large molecule drugs, such as proteins, antibodies, oliogonucleotides, ADC and new modalities. We have available all common laboratory animal species such as non-human primates, canines, minipigs, mice, rats, rabbits, etc.

Read More...

Download PDF